Drug Development

ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen

22nd August 2018

ViiV Healthcare announced positive headline results from its global, phase III ATLAS study of a long-acting, injectable two-drug regimen (2DR)...

U.S. FDA approves opdivo as the first new medication in nearly 20 years for certain patients with previously treated small cell lung cancer

by Content Team

17th August 2018

Bristol-Myers Squibb Company announced that Opdivo (nivolumab) received approval from the U.S. FDA as the first and only Immuno-Oncology treatment...

Eisai And Merck announce FDA approval of LENVIMA capsules for first-line treatment of Unresectable Hepatocellular Carcinoma

by Content Team

16th August 2018

Eisai Inc. and Merck , known as MSD outside of the United States and Canada , announced that the U.S....

Bayer and Haplogen collaborate to develop new treatments against pulmonary diseases

by Content Team

16th August 2018

Bayer and Haplogen GmbH, a Vienna-based biotechnology company, have entered into a multi-year research collaboration agreement to identify new drug...

Large Pharmaceutical Company in China Selects TrialMaster® EDC and Acuity Analytics for Major Clinical Study

by Content Team

16th August 2018

In a milestone transaction, a major pharmaceutical company based in China will undertake a multisite clinical study using TrialMaster EDC...

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza

by Content Team

16th August 2018

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, announced...

Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

by Content Team

16th August 2018

Teva Pharmaceutical Industries Ltd. and Regeneron Pharmaceuticals, Inc. announced positive topline results from a Phase 3, randomized, double-blind, placebo-controlled study...